Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - fluvoxamine maleate -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - fluvoxamine maleate -

United States - English - NLM (National Library of Medicine)

american health packaging - fluvoxamine maleate (unii: 5lgn83g74v) (fluvoxamine - unii:o4l1xpo44w) - fluvoxamine maleate 50 mg

United States - English - NLM (National Library of Medicine)

golden state medical supply, inc. - fluvoxamine maleate (unii: 5lgn83g74v) (fluvoxamine - unii:o4l1xpo44w) - fluvoxamine maleate 25 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - fluvoxamine maleate, quantity: 100 mg - tablet, film coated - excipient ingredients: titanium dioxide; mannitol; macrogol 8000; magnesium stearate; hyetellose; iron oxide red; iron oxide yellow; iron oxide black - indicated for the treatment of major depression in adults. indicated for the treatment of obsessive compulsive disorder in children aged 8 years of age and older, adolescents, and adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - fluvoxamine maleate, quantity: 50 mg - tablet, film coated - excipient ingredients: titanium dioxide; macrogol 8000; magnesium stearate; mannitol; hyetellose; iron oxide yellow - indicated for the treatment of major depression in adults. indicated for the treatment of obsessive compulsive disorder in children aged 8 years of age and older, adolescents, and adults.

United States - English - NLM (National Library of Medicine)

avpak - fluvoxamine maleate (unii: 5lgn83g74v) (fluvoxamine - unii:o4l1xpo44w) - fluvoxamine maleate tablets are indicated for the treatment of obsessions and compulsions in patients with obsessive compulsive disorder (ocd), as defined in dsm-iii-r or dsm-iv. the obsessions or compulsions cause marked distress, are time-consuming, or significantly interfere with social or occupational functioning. obsessive compulsive disorder is characterized by recurrent and persistent ideas, thoughts, impulses or images (obsessions) that are ego-dystonic and/or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable. the efficacy of fluvoxamine maleate tablets was established in four trials in outpatients with ocd: two 10-week trials in adults, one 10-week trial in pediatric patients (ages 8 to 17), and one maintenance trial in adults [see clinical studies ( 14)]. coadministration coadministration of tizanidine, thioridazine, alosetron, or pimozide with fluvoxamine maleate tablets is contraindicated

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - fluvoxamine maleate -

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - fluvoxamine maleate -

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - fluvoxamine maleate, quantity: 100 mg - tablet, film coated - excipient ingredients: mannitol; maize starch; pregelatinised potato starch; sodium stearylfumarate; colloidal anhydrous silica; hypromellose; macrogol 6000; purified talc; titanium dioxide - movox (fluvoxamine maleate) is indicated for the treatment of major depression in adults. movox (fluvoxamine maleate) is also indicated for the treatment of obsessive compulsive disorder (ocd) in both children aged 8 years and older, adolescent, and adults.